253
Views
6
CrossRef citations to date
0
Altmetric
Clinical Features - Case Report

Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections

, , , &
Pages 239-240 | Received 20 Dec 2018, Accepted 25 Jan 2019, Published online: 08 Feb 2019

References

  • Menon K, Van Voorhees AS, Bebo BF Jr., et al. National Psoriasis Foundation. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(2):291–299.
  • Bardazzi F, Magnano M, Campanati A, et al. Biologic therapies in HIV-infected patients with psoriasis: an Italian experience. Acta Derm Venereol. 2017 Aug 31;97(8):989–990.
  • Bonifati C, Lora V, Graceffa D, et al. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444–6455.
  • Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23–32.
  • Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77(2):310–317.e1.
  • Gooderham M, Papp K. Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast. BioDrugs. 2015;29(5):327–339.
  • Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019 Jan;80(1):43–53.
  • Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;31(11):e481–e482.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.